Vanderbilt Institute for Clinical and Translational Research (VICTR)

联系PD/PI：Bernard，Gordon R 范德比尔特临床和转化研究所（VICTR）是一个功能强大， 综合临床和转化（C&T）研究基础设施，提高了质量， 科学严谨的研究进行了范德比尔特和长期合作伙伴梅哈里， 美国历史上最古老的黑人学术健康科学机构。卢旺达问题国际法庭将协助 在利用卢旺达问题国际刑事法庭内部独特的资源和专门知识的同时， 通过这些新目标，在C&T研究中集中和提升健康公平的作用：1）杠杆 VICTR强大的协作能量，以加强团队科学方法，整合 社区参与原则的所有阶段的研究，并实施方案设计 支持研究中的健康公平; 2）开发和共享多维数据组织 方法和信息工具，以宣传创新，效率，质量和公平的研究; 3)确保翻译科学的劳动力是多样化的，并具有技能，知识， 在健康公平框架内推动成果转化所需的资源; 4） 支持地方研究的效率、质量、代表性和影响，并“提高标准” 5）支持研究的效率，质量， 通过建立和传播多中心临床试验， 简化程序并促进新颖的试验设计;以及6）利用独特的机构 能够在医疗保健操作期间进行实用试验， 现有药物用于新适应症。

Contact PD/PI: Bernard, Gordon R The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub and elevating the role of health equity in C&T research with these new aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies, integrate community engagement principles for all stages of research, and implement programs designed to support health equity in research; 2) Develop and share multi-dimensional data organization methods and informatics tools to promulgate innovation, efficiency, quality, and equity in research; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries within a health equity framework; 4) Support the efficiency, quality, representativeness, and impact of local studies and `raise the bar' for acceptable scientific standards in research conduct; 5) Support the efficiency, quality, representativeness, and impact of multi-site clinical trials by building and disseminating streamlining programs and promoting novel trial designs; and 6) Utilize unique institutional capabilities to enable the conduct of pragmatic trials during healthcare operations and repurpose existing drugs for new indications.